Mentions
Extended reach
Total likes
Video views
AI synopsis
Numerous discussions highlight the significant outcomes from the RALES trial, with users citing the 30% reduction in mortality and decreased hospitalizations due to heart failure. Phrases like 'transformed treatment' and 'landmark study' convey the transformative potential attributed to spironolactone. The consistent repetition of these impactful results emphasizes the study's relevance, showing how the choice of words creates a strong narrative around its importance.
The discussions reflect strong support for the findings of the RALES trial, with multiple posts emphasizing its significance in treatment protocols.
There is a high level of curiosity surrounding the study's implications for heart failure management, as users reference and discuss its impact on mortality rates.
Participants engage deeply with the content, analyzing specific outcomes and drawing connections to other studies in the field.
The consensus is that the findings from the study will have considerable influence on clinical practice, particularly in cardiology.
Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. https://t.co/TeVmDHis7d
Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can literally be the difference between life and death. https://t.co/jbNptPsi1S
The effect of spironolactone on morbidity and mortality in patients with severe heart failure https://t.co/8djc87Mrvt
スピロノラクトンが心不全患者の予後を劇的に改善したことを示したRALESを改めて読んでるんだけど、とても味わい深い。総死亡リスクのHRが0.70倍、NNTが9人だもんなぁ。 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. https://t.co/DGiBMLIFXc
Pour le papier complet, c'est ici RALES, c'est l’acronyme de Randomized ALdactone Evaluation Study. Il s’agissait de tester les effets d’un médicament nommé spironolactone, ou aldactone (nom commercial), chez les patients insuffisants cardiaques. Simple. https://t.co/6oL1mbu8fB
But she was also on spironolactone for heart failure, I think because of a blockbuster study published a few years earlier: The Randomized Aldactone Evaluation Study (RALES) https://t.co/BgSZmtZIKT /7
This study evaluates whether cerebral embolic protection devices reduce disabling strokes in TAVR patients, showing significant benefits especially in high-risk groups. Findings suggest EPDs may help decrease severe…
This week, John Mandrola MD discusses the significant findings of a study involving 1,663 patients with severe heart failure. The research shows that spironolactone, when added to standard treatment, can reduce death…
This week, we discuss exercise-related sudden cardiac death and new findings in TAVI data. The podcast also explores the health effects of coffee on cardiac activity and physical performance. Join John Mandrola, MD, for…
Hola @grok, háblame del estudio RALES, The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
@enango スピロノラクトンを重症心不全患者(EF＜35%)に投与試験(RALES試験NEJM1999年)では ・死亡率30%(0.60 to 0.82; P<0.001)低下 ・この効果は虚血性でも得られた https://t.co/v3fAWHFUT5 ・軽症心不全のEMPHASIS-HF試験でも良い結果 https://t.co/ERG2QoEkKC 今回、心筋梗塞で死亡等減少なしの結果??
@Cafe_Dogtor 重症心不全患者(EF＜35%)にスピロノラクトン投与したRALES試験(NEJM1999年)では ・死亡率30%(0.60 to 0.82; P<0.001)低下 ・この効果は虚血/非虚血ともに得られたhttps://t.co/v3fAWHFUT5 ・軽症心不全のEMPHASIS-HF試験でも良い結果https://t.co/ERG2QoEkKC 今回、心筋梗塞で死亡等減少なしの結果?? https://t.co/ynI4fZo0sz
@twmu_cardiology 重症心不全患者(EF＜35%)にスピロノラクトン投与したRALES試験(NEJM1999年)では死亡率30%(0.60 to 0.82; P<0.001)低下。 この効果は虚血/非虚血ともに得られた結果でした。 軽症心不全のEMPHASIS-HF試験でも良い結果。 今回、心筋梗塞で良い結果が得られなかったのか??? https://t.co/v3fAWHFUT5 https://t.co/UgiaYaNX4A
@tcross_news 重症心不全患者(EF＜35%)にスピロノラクトン投与したRALES試験(NEJM1999年)では死亡率30%(0.60 to 0.82; P<0.001)低下。 この効果は虚血/非虚血ともに得られた結果でした。 軽症心不全のEMPHASIS-HF試験でも良い結果。 今回、心筋梗塞で良い結果が得られなかったのか??? https://t.co/v3fAWHFUT5
@irjpnmEqqEUJraX 重症心不全患者(EF＜35%)にスピロノラクトン投与したRALES試験(NEJM1999年)では死亡率30%(0.60 to 0.82; P<0.001)低下。 この効果は虚血/非虚血ともに得られた結果でした。 軽症心不全のEMPHASIS-HF試験でも良い結果。 今回、心筋梗塞で良い結果が得られなかったのか??? https://t.co/v3fAWHFUT5 https://t.co/rZ1XA7GfDZ
@Office_j 重症心不全患者(EF＜35%)にスピロノラクトン投与したRALES試験(NEJM1999年)では死亡率30%(0.60 to 0.82; P<0.001)低下。 この効果は虚血/非虚血ともに得られた結果でした。 軽症心不全のEMPHASIS-HF試験でも良い結果。 今回、心筋梗塞で良い結果が得られなかったのか??? https://t.co/v3fAWHFUT5 https://t.co/QiiWsMsyJZ
Pour le papier complet, c'est ici RALES, c'est l’acronyme de Randomized ALdactone Evaluation Study. Il s’agissait de tester les effets d’un médicament nommé spironolactone, ou aldactone (nom commercial), chez les patients insuffisants cardiaques. Simple. https://t.co/6oL1mbu8fB
@era1521 @glenpyle Yes. The spironolactone trial in heart failure was stopped early (2 years) after definitive evidence accrued showing that deaths were much lower in the treated group. There are more modern examples. https://t.co/S9PkDDFVWf
15/
@TBaubet @DavidJuurlink Etape 1 : publication sur l'intérêt de la spironolactone dans l'insuffisance cardiaque... https://t.co/6oL1mbu8fB
RT @goat_invest: @Moistjp Randomized ALdactone Evaluation Studyの頭文字でRALSE試験、これがスピロノラクトンの予後改善効果のエビデンスになる試験なんですね。こちらが一番最初のエビデンスでしょうか？しっかり1次情報…
@Moistjp Randomized ALdactone Evaluation Studyの頭文字でRALSE試験、これがスピロノラクトンの予後改善効果のエビデンスになる試験なんですね。こちらが一番最初のエビデンスでしょうか？しっかり1次情報まで確認しないとダメですね。ありがとうございます
RT @cardiomet_CE: 11b) Adding #spironolactone to the standard of care #SOC among patients with severe #HF improved survival & reduced morb…
11b) Adding #spironolactone to the standard of care #SOC among patients with severe #HF improved survival & reduced morbidity in the landmark Randomized Aldactone Evaluation Study (#RALES) trial
RT @ckd_ce: 11b) Adding #spironolactone to the standard of care #SOC among patients with severe #HF improved survival & reduced morbidity i…
11b) Adding #spironolactone to the standard of care #SOC among patients with severe #HF improved survival & reduced morbidity in the landmark Randomized Aldactone Evaluation Study (#RALES) trial
RT @syuichiao89: うそんこ言ってるから気を付けや
うそんこ言ってるから気を付けや
@GidMK Perhaps the RALES Trial, however, previous observational studies were limited by hyperkalemia. https://t.co/Wj0pyEVC5a
RALES - The Effect of Spironolactone on Morbidity and Mortality in
REFERENCES: https://t.co/DHeQkVseWx https://t.co/EMv5WLE6tu
RT @cardiomet_CE: 21) Blockade of the #MR with spironolactone in pts w/#HFrEF (RALES; N = 1663) yielded 30% ⬇️ risk of death vs placebo (
21) Blockade of the #MR with spironolactone in pts w/#HFrEF (RALES; N = 1663) yielded 30% ⬇️ risk of death vs placebo (
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
RT @drscottyk: Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can liter…
Spironolactone in HFrEF: 11% absolute risk reduction in mortality in just 2 years! Maximizing and optimizing GDMT can literally be the difference between life and death. https://t.co/jbNptPsi1S
RT @ckd_ce: 21) Blockade of the MR with spironolactone in pts w/HFrEF (RALES; N = 1663) yielded 30% ⬇️ risk of death vs placebo (
21) Blockade of the MR with spironolactone in pts w/HFrEF (RALES; N = 1663) yielded 30% ⬇️ risk of death vs placebo (
RT @CONAREC_ORG: The effect of spironolactone on morbidity and mortality in patients with severe heart failure https://t.co/8djc87Mrvt
RT @CONAREC_ORG: The effect of spironolactone on morbidity and mortality in patients with severe heart failure https://t.co/8djc87Mrvt
RT @CONAREC_ORG: The effect of spironolactone on morbidity and mortality in patients with severe heart failure https://t.co/8djc87Mrvt
RT @CONAREC_ORG: The effect of spironolactone on morbidity and mortality in patients with severe heart failure https://t.co/8djc87Mrvt
RT @CONAREC_ORG: The effect of spironolactone on morbidity and mortality in patients with severe heart failure https://t.co/8djc87Mrvt
RT @CONAREC_ORG: The effect of spironolactone on morbidity and mortality in patients with severe heart failure https://t.co/8djc87Mrvt
The effect of spironolactone on morbidity and mortality in patients with severe heart failure https://t.co/8djc87Mrvt
The effect of spironolactone on morbidity and mortality in patients with severe heart failure https://t.co/aLD5Zp8DiQ
Read the full article here: https://t.co/5PbWDxoImL
28) In the RALES trial (
【SY10-2】MRAと心不全 https://t.co/HPG6B0zz8U https://t.co/n5AqI7ginq #jsnp2021
21) Blockade of the MR with spironolactone in pts w/HFrEF (RALES; N = 1663) yielded 30% ⬇️ risk of death vs placebo (doi: 10.1056/NEJM199909023411001); the trial was stopped prematurely for efficacy, including ⬇️progressive #heartfailure ⬇️sudden death & ⬇️hosp for heart failure. https://t.co/lgDHQo1IhM
(6/n) The incidence of this adverse effect has been quantified in said clinical trials. For example, the RALES study found that patients with heart failure treated with spironolactone had a 1.7% incidence of serious hyperkalemia versus 1.2% with placebo. https://t.co/Xf42J3hNQD
RALES 1999
@Jwaitz @girish_nadkarni @hswapnil @medrants Slow your role there. Rales study did not require beta blockers, just an ACEi. https://t.co/uWXY6DkG6c https://t.co/g1iVIyK5YJ
心不全に「スピロノラクトン」を使ったら安全に死亡・入院が減ったで～ていうRALES試験。 N Engl J Med. 1999 Sep 2;341(10):709-17. https://t.co/9C8X0RtrnB RALES試験の外的妥当性を考えずに使いまくったら高Ｋ血症が増えた件。 N Engl J Med. 2004 Aug 5;351(6):543-51. https://t.co/WQztSDsDhp
RALES: The use of spironolactone in patients with severe HF was associated with reduction in mortality related to HF and sudden death, as well as decreased hospitalizations for HF and improvement in functional status #UMKCRCT https://t.co/vJFG730Xwz
RT @DavidJuurlink: But she was also on spironolactone for heart failure, I think because of a blockbuster study published a few years earli…
But she was also on spironolactone for heart failure, I think because of a blockbuster study published a few years earlier: The Randomized Aldactone Evaluation Study (RALES) https://t.co/BgSZmtZIKT /7
@Proximal_Baxi @TWhittier_RUSH @NephRodby @kidney_boy @AnnaGaddy @NephroPeeps @Jwaitz @BookBurton @melhoenig @LeticiaRolonMD @amyaimei @DTomacruzMD And this https://t.co/uqATLqeKyQ Aldo FTW https://t.co/uEsREJwJLW
Moving forward to 1999 came RALES, supporting spironolactone use, following by EPHESUS in 2003 giving evidence for eplerenone in pts with LVSD post MI. https://t.co/MW8kWdubQv https://t.co/UX5QLLmkxP (Prof Pfeffers #ESCCongress talk) 6/ https://t.co/VeeCC0qtQb
Quien quiere analizar un estudio icono de la insuficiencia cardíaca ? https://t.co/OX4ZF2F0Bk
RT @FredLAFernandes: Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. ht…
RT @FredLAFernandes: Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. ht…
RT @FredLAFernandes: Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. ht…
RT @FredLAFernandes: Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. ht…
RT @FredLAFernandes: Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. ht…
RT @FredLAFernandes: Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. ht…
RT @FredLAFernandes: Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. ht…
RT @FredLAFernandes: Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. ht…
RT @FredLAFernandes: Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. ht…
Estudos clássicos sobre o assunto Espironolactona em IC leve https://t.co/0fC0m12KT1 Espironolactona em IC grave. https://t.co/TeVmDHis7d
@CMichaelGibson Two decades and 8 months...spironolactone. https://t.co/yDrpn8Aket
Pero en realidad el estudio había demostrado reducción del riesgo del desenlace primario y baja tasa de hipercalemia severa. https://t.co/1jcmyf5mql
RT @89089314: スピロノラクトンが心不全患者の予後を劇的に改善したことを示したRALESを改めて読んでるんだけど、とても味わい深い。総死亡リスクのHRが0.70倍、NNTが9人だもんなぁ。 The effect of spironolactone on morbid…
スピロノラクトンが心不全患者の予後を劇的に改善したことを示したRALESを改めて読んでるんだけど、とても味わい深い。総死亡リスクのHRが0.70倍、NNTが9人だもんなぁ。 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. https://t.co/DGiBMLIFXc
RT @MedEdPGH: #EBMondays Oldie but goodie: RALES Trial Spironolactone 25mg daily added to the regimen of patients with HFrEF (EF<35%) wit…
Fizz先生のツイートに触発されて…。 RALES試験か。ふむ、試験対象群が６５±１２歳。 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. - PubMed - NCBI https://t.co/iQJpfhl43e
RT @jsenior64: Posteriormente nos mostraron los efectos sobre desenlaces importantes; redujo la mortalidad en un 30% tanto por progresión c…
Posteriormente nos mostraron los efectos sobre desenlaces importantes; redujo la mortalidad en un 30% tanto por progresión como por muerte súbita. Recuerden un dato interesante sólo el 11% tomaban betabloqueadores. https://t.co/1jcmyf5mql
RT @MedEdPGH: #EBMondays Oldie but goodie: RALES Trial Spironolactone 25mg daily added to the regimen of patients with HFrEF (EF<35%) wit…
RT @MedEdPGH: #EBMondays Oldie but goodie: RALES Trial Spironolactone 25mg daily added to the regimen of patients with HFrEF (EF<35%) wit…
RT @MedEdPGH: #EBMondays Oldie but goodie: RALES Trial Spironolactone 25mg daily added to the regimen of patients with HFrEF (EF<35%) wit…
#EBMondays Oldie but goodie: RALES Trial Spironolactone 25mg daily added to the regimen of patients with HFrEF (EF<35%) with NYHA class III-IV symptoms reduced mortality by 30%. https://t.co/NyckUb9p7U